Drug intelligence / Profile preview

BK-SE36 + CpG

Development stage: Unknown
Lead developer: Nobelpharma
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

BK-SE36 + CpG is a recombinant protein subunit vaccine candidate designed to prevent blood-stage *Plasmodium falciparum* malaria. It consists of the N-terminal domain of the *P. falciparum* serine repeat antigen 5 (SERA5/SE36) protein, which is adsorbed to an aluminum hydroxide gel (forming BK-SE36) and co-administered with the synthetic oligodeoxynucleotide adjuvant CpG-ODN(K3). The CpG-ODN(K3) component acts as a Toll-like receptor 9 (TLR9) agonist to enhance the immunogenicity of the SE36 antigen. Developed by Nobelpharma in collaboration with researchers at Osaka University, the vaccine aims to induce protective antibodies against the parasite's blood-stage infection. It has undergone Phase 1 clinical evaluation in both malaria-naïve Japanese adults and malaria-exposed populations in Burkina Faso.

Other names: BK-SE36 adjuvanted with CpG-ODN(K3)

Targets

SERA5 (Plasmodium falciparum serine repeat antigen 5)TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on BK-SE36 + CpG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BK-SE36 + CpG.

Explore the full profile